Questions
How did Moderna make a vaccine so quickly after the virus appeared?
Bancel says mRNA is an information molecule, so Moderna designed the vaccine on a computer from the virus's published genetic sequence and robots made it. The manufacturing process stays the same, and only the order of the genetic letters changes, so the first human trial began about two months after the sequence was released.
Why did Moderna slow down its main clinical trial?
Bancel says the trial was recruiting too few African-American volunteers. Moderna feared that a community with a history of being mistreated in medical studies would not trust the vaccine, so it shut some sites and opened a new one to recruit more.
What does it mean that mRNA is a platform technology?
Bancel says every Moderna product uses the same four genetic letters and the same factories, so learning carries over from one product to the next. He compares Moderna to Netflix rather than a blockbuster, where each traditional drug is made differently.
Will people need COVID shots every year?
Bancel expects a yearly booster, adapted to that year's variant and possibly combined with flu and RSV, rather than a lifetime vaccine. He says the virus's mutations should slow because the spike protein's genetic code is finite, but this is his expectation, not a certainty.
How does Moderna handle drugs that cannot make money?
Bancel says there are about a dozen rare diseases where the price needed to break even would be obscene. He says Moderna would rather do these through partnerships with foundations or governments, as it did by giving a Crigler-Najjar drug to a foundation, and the same approach could cover tropical diseases.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Stephane Bancel says he first learned of a new pneumonia-like disease in Wuhan, China from a Wall Street Journal article read on holiday in the south of France just after Christmas 2019.
“And there was a Wall Street Journal article that I read when I was actually in the south of France on vacation just a few days after Christmas 2019”
0:00:37 · Stephane Bancel · Outbreak awareness · 2019
Bancel says Moderna waited for January 10, when Chinese researchers posted the new coronavirus's genetic sequence online.
“So we waited for January 10, when the Chinese put this genetic sequence online.”
0:01:20 · Stephane Bancel · Virus sequence · 2020
Bancel says he realised at Davos in the week of January 20, 2020 that the virus would be a pandemic like 1918, and he then made COVID-19 Moderna's top priority.
“It's only when I'm in Davos the week of January 20 that I realized that this was going to be a pandemic like 1918.”
0:01:45 · Stephane Bancel · Pandemic recognition · 2020
Bancel says Moderna had worked on its mRNA technology for about 10 years and had put nine vaccines into human testing before COVID-19 appeared.
“we have this technology that we've been working on for 10 years we've done 9 vaccines in human testing when COVID-19 appears”
0:02:17 · Stephane Bancel · mRNA technology · 2020
Host Nicolai Tangen says Moderna went from the first virus sequence in January 2020 to a vaccine in a phase one clinical trial two months later.
“Now, you went from the first sequence of a virus in January 2020 to a vaccine in phase one clinical trial two months later.”
0:03:21 · Nicolai Tangen · Development speed · 2020
Bancel says Moderna designs its vaccines on a computer from genetic data and then sends the instructions to robots that make the vaccine.
“We use genetic information, so just data, to design the vaccine on the computer. And then the instructions go to robots, and the robots start making the vaccine.”
0:03:57 · Stephane Bancel · Vaccine design
Bancel says Moderna's manufacturing process is the same for every mRNA vaccine, and the only difference between flu, COVID and Zika vaccines is the order of the genetic letters.
“Because the only difference with flu vaccine and COVID vaccine and Zika vaccine is only the orders of the letters on the message.”
0:03:57 · Stephane Bancel · Manufacturing process
Bancel says Moderna's team began working seven days a week around February 2020 and kept that up for nine months.
“We started around February of 2020 to actually work seven days a week which was dreadful because it was not a few weekends it was for nine months”
0:04:27 · Stephane Bancel · Workload · 2020
Bancel says Moderna started its phase three COVID-19 vaccine study on July 26, 2020.
“we started a phase three study in July 26 of 2020.”
0:06:03 · Stephane Bancel · Phase three trial · 2020
Bancel says Moderna shut down some trial sites that were enrolling only white people and opened a new site to recruit more African-Americans.
“We actually shut down a few of the clinical trial sites where they were enrolling only white people and focusing energy and opening a new site to do more recruiting of African-Americans.”
0:06:55 · Stephane Bancel · Trial diversity · 2020
Bancel says Moderna was among the first companies in Massachusetts to set up its own testing lab, in spring 2020, so candidates could be tested for onsite interviews.
“We set up our own lab, which we were one of the first companies in Massachusetts to set up our own lab back in the spring of 2020.”
0:08:49 · Stephane Bancel · Hiring · 2020
Bancel says he publicly appealed on TV and radio for Moderna to hire 500 people in Cambridge or Norwood, Massachusetts, where its plant was.
“I will be sometime on TV or on radio saying, hey, we need to hire 500 people in Cambridge or in Norwood where our plant was.”
0:10:31 · Stephane Bancel · Hiring · 2020
Bancel says Moderna's Massachusetts plant made $600 million in 2021 and runs entirely without paper.
“If you look at our plant in Massachusetts that has made $600 million last year in 2021, there is no paper in that plant.”
0:11:18 · Stephane Bancel · Digital manufacturing · 2021
Bancel says Moderna had to choose the phase three dose without full phase two antibody data.
“we had to pick the dose for phase three without the full dose for phase two data.”
0:13:00 · Stephane Bancel · Dose selection · 2020
Bancel says Moderna chose a 100-microgram dose for its COVID-19 vaccine, which he believes gave longer protection than other vaccines.
“So we ended up picking 100 micrograms, which ended up giving the Mona vaccine a much longer duration of protection than the other vaccines.”
0:13:54 · Stephane Bancel · Dose selection · 2020
Bancel says he was raised by the Jesuits, which gave him a serving mindset that shaped his career in life science.
“I was raised by the Jesuits so kind of a serving mindset I've been in life science all my life”
0:02:17 · Stephane Bancel · Background
Bancel says he and his wife have started two foundations, which his wife runs.
“We have now actually two foundations that we've started that my wife is running.”
0:15:15 · Stephane Bancel · Philanthropy
Bancel says Moderna has 46 drugs in development and expects soon to have 80 or 90.
“Now we have now 46 drugs in development, which is a lot.”
0:16:59 · Stephane Bancel · Drug pipeline · 2022
Bancel previously ran BioMérieux, a French diagnostics company built by the Mérieux family.
“I used to run BioMérieux. It's a French-based diagnostic company. It was built by a family, the family of Marieux.”
0:17:46 · Stephane Bancel · Career history
Bancel says Moderna gave a drug for a rare genetic disease to a foundation in the fall before this interview.
“we recently, in the fall, we gave away a drug for rare genetic disease to a foundation.”
0:18:42 · Stephane Bancel · Drug donation · 2021
Bancel says that for the rare disease Crigler-Najjar, Moderna would have had to charge about $1 million per child per year just to cover its clinical costs.
“we realized that because the number of kids is so small, if we just want to break even our clinical costs, we will have to charge a family around $1 million per year per kid.”
0:19:17 · Stephane Bancel · Drug pricing
Bancel says Moderna committed by contract to supply the approved drug free every year to the couple of hundred affected children worldwide.
“And we committed by contract that if the drug is approved, we will every year supply to those couple hundred kids in the planet.”
0:20:41 · Stephane Bancel · Drug donation
Bancel says more people in Africa are dying of malaria than of COVID.
“If you look at the numbers in Africa, you have more people dying of malaria today than COVID.”
0:21:31 · Stephane Bancel · Tropical disease · 2022
Bancel says Moderna's vision is a once-a-year booster combining COVID, flu, RSV and other coronavirus protection.
“So our vision is to save millions of lives every year by providing a once a year booster that has COVID in it”
0:23:40 · Stephane Bancel · Combination booster
Bancel says the spike protein's genetic code has about 4,000 letters, which limits how many mutations are possible.
“The spike protein has 4 ,000 letters in it, genetic letters.”
0:24:36 · Stephane Bancel · Virus mutation
Bancel says China shows little appetite for foreign vaccines, which he sees as a problem for its zero-COVID policy.
“There's not a lot of appetite today to get foreign vaccine used in China.”
0:25:56 · Stephane Bancel · China policy · 2022